Roche: BofA Global Research ups target price

(CercleFinance.com) - On Tuesday BofA Global Research has raised its target price for the Roche share from 345 Swiss francs to 360 Swiss francs, while reiterating its Buy rating.


According to analysts, the market is underestimating the size of the Swiss pharmaceutical group's drugs pipeline in FY 2020.

They add that there are numerous results of phase III studies - particularly concerning risdiplam (spinal muscular atrophy syndrome), etrolizumab (Crohn's disease) or Lucentis (AMD) - due this year.

In its comments, BofA also highlights the share's valuation, which is deemed "attractive," as well as better visibility regarding generic erosion in the US.


Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.